Pulsetto vs Quietaa vs Truvaga vs Nurosym

60-Day Trial

Rated 4..5/5 | Loved by 10K+ customers

Pulsetto vs Quietaa vs Truvaga vs Nurosym: A Spec Comparison for HRV Trackers, Recovery-Stack Builders, and Anyone Tired of Subscription Wellness

Four cervical and auricular vagus nerve stimulators. Different waveforms. Different intensity ranges. Different app dependencies. Different cost trajectories over three years. We make one of them. We have included it in this comparison because no one else was writing this guide. Where our device is not the right fit, we say so.

WRITTEN BY THE QUIETAA TEAM · PUBLISHED MAY 2026 · LAST UPDATED MAY 25, 2026 · 13-MINUTE READ

INTRODUCTION

Why this guide exists

If you're reading this, you've already done the spreadsheet on at least one of these devices. You wear an Oura, a Whoop, or both. You have an Eight Sleep, or you've researched one. You stack AG1, magnesium glycinate, ashwagandha, and creatine. You've done the cold plunge sequence and the sauna protocol. You have a Levels CGM somewhere in a drawer. You know your three-month HRV trend better than you know your own credit card statement.

And the needle on the variable that actually matters — your nervous system's ability to regulate itself — is not moving the way the rest of your stack is moving.

You've already read enough to know what to do about it. Cervical vagus nerve stimulation has the cleanest mechanism-anchored evidence base of any non-pharmacological intervention for HRV improvement, autonomic balance, and sympathetic-parasympathetic tone correction. The published research is real. The modality works. The consumer devices have been good enough for at least two years.

The actual question is which one to buy.

This is a comparison of the four cervical or auricular vagus nerve stimulators currently in serious contention for that decision: Pulsetto, Truvaga, Nurosym, and Quietaa. We make one of them. We have included it in this comparison because no one else was writing this guide honestly — what existed was either affiliate-driven listicle pages with manufactured "Best of 2026" rankings, or single-brand pages explaining why their device was best without referencing any of the others.

This guide does not score. It does not rank. It compares. The decision matrix at the bottom tells you which device fits which use case, including the cases where Quietaa is not the right answer.

Transparency

Disclosure: who we are
and what is at stake

This guide was written by the team that built Quietaa. We made it because the comparison content we wanted to read for our own community — the recovery-stack builders, the HRV trackers, the people who have already done the cold plunge and the supplements and the breathwork and the cognitive-load management — did not exist in honest form.

You should know two things going in.

First, we have a financial stake in the answer. If you buy Quietaa, our team gets paid. We have written this guide knowing that, and we have tried to keep it honest enough that you would forgive us for that fact.

Second, we will tell you when Quietaa is not the right answer. Where Truvaga is the better fit, we say so. Where Nurosym is the better fit, we say so. The decision matrix at the bottom of this guide is not a sales tool; it is the honest filter you would apply if you were on our team.

What you will also notice in the section below is that we have not been diplomatic about Pulsetto. There is a reason for that, and we will name it directly.

Transparency

The Pulsetto problem,
briefly

If you're reading this, there's a good chance you've already been around the Pulsetto block.

You bought one. You used it for a few weeks. The hardware was fine — the bilateral cervical stimulation does what it says on the tin, and the sessions were short enough to fit into your morning protocol. Then you noticed something: the device kept asking you to subscribe to the app to unlock "premium" programmes. Then your card got hit for a monthly fee you don't quite remember opting into. Then you tried to cancel, and the path was friction. Then you tried to return the device, and the return window was 30 days from purchase, not 30 days from the moment you realised this wasn't going to work for you.

Or maybe you didn't buy one yourself, but you read the threads. r/Biohackers, r/VagusNerve, r/POTS, r/Anxiety — the pattern is consistent across communities. The hardware works. The company, increasingly, does not.

This comparison exists because that trust failure created a market opening.

Quietaa was built explicitly on the depositioning of Pulsetto. Same modality. Same fundamental mechanism. The neck collar form factor, the bilateral cervical electrode placement, the 10-minute session length. Roughly half the lifetime cost. No subscription. No app paywall. No automatic re-billing. No "premium tier" that locks the sessions you bought the device for behind a monthly fee.

Where Pulsetto runs the playbook of monetizing post-purchase, Quietaa runs the playbook of monetizing once and then leaving you alone.

Truvaga and Nurosym are real alternatives in this category, with different modalities and different evidence profiles, and the rest of this guide walks through them honestly. But the reason you are reading this and not just buying another Pulsetto is structural — you have lost trust in the leader and you want to know what the second wave looks like.

This guide is the second wave, written by one of the brands competing in it.

Technical primer

A brief technical primer

Three forms of non-invasive vagus nerve stimulation are represented in this guide. Skip this section if you already know it.

Bilateral cervical tVNS — electrodes on both sides of the neck, simultaneous stimulation of both vagus branches. The Pulsetto and Quietaa form factor. Hands-free during the session. The modality with the most direct cardiovascular and autonomic evidence base.

Unilateral cervical tVNS — handheld device pressed against one side of the neck for short timed bursts, alternating sides between sessions. The Truvaga form factor. The most clinically pedigreed signal architecture in the category — Truvaga's parent company also makes the FDA-cleared gammaCore device. Requires physically holding the device during sessions.

Auricular tVNS — electrode clipped to the concha or tragus of the ear, stimulating the auricular branch of the vagus nerve. The Nurosym form factor. Longer session protocols. The modality with the deepest inflammation, GI, and long-COVID research base.

These three modalities are not interchangeable. They feel different. They are protocolled differently. The evidence varies by indication. The cards below address this for each.

Technical primer

Technical specifications

Pricing & trial

Across the four devices in this comparison, the difference in 3-year total cost between the highest and lowest option is approximately $410. The difference in return-window length is 30 days.

Pulsetto’s subscription model accounts for $282–$432 of the cost gap between it and Quietaa over three years. Truvaga and Nurosym, both of which moved away from or never adopted subscription pricing, are competitive on lifetime cost despite higher (Nurosym) or comparable (Truvaga) upfront pricing. The “subscription premium” is a Pulsetto-specific phenomenon at this point in the category.

Source: Lifetime cost calculations based on each manufacturer’s published pricing as of May 2026.

Pricing verified against each manufacturer's site as of May 2026. Subscription tiers, Plus availability, and return terms change frequently — verify on the brand site at time of purchase.

Deep dive

the four devices in detail

The cards below use the same structure for each product. We have ordered them by the order most readers will already have encountered them — Pulsetto first because that is most likely your starting point; Quietaa last because we are not going to visually elevate our own product in this comparison.

Pulsetto

MANUFACTURER

Pulsetto (European)

MODALITY

Bilateral cervical tVNS (collar-style, worn around the neck)

FORM FACTOR

Wearable neck collar with paired electrodes

TREATMENT PROTOCOL

4 to 20 minute sessions, typically once or twice daily. Programme selection requires the companion app to be open and Bluetooth-connected.

TECHNICAL SPECS

Bilateral simultaneous stimulation. Four intensity levels. Specific pulse-width, frequency, and waveform parameters are not published in detail on the Pulsetto product page; the device operates within the general parameter range of the broader cervical-tVNS research base.

APP / SUBSCRIPTION REQUIRED

Yes. Bluetooth pairing with the Pulsetto companion app is required to access the full programme library. Pulsetto Premium subscription (approximately $96–$144 per year depending on tier) unlocks the complete session library. Without the subscription, a limited set of sessions is available on the free tier.

DATA EXPORT / HRV INTEGRATIONS

No native Oura, Whoop, or Apple Health integration as of mid-2026. In-app HRV self-reporting only.

REGULATORY STATUS

Not FDA-cleared as a medical treatment. Sold as a general wellness device. CE-marked in Europe.

WARRANTY

12-month manufacturer warranty.

PRICE STRUCTURE

Approximately $278 USD on-sale (RRP $478) plus $96–$144 per year subscription for full access. Realistic 3-year total cost: approximately $560–$710. Realistic 5-year total cost: approximately $750–$1,000+.

RETURN POLICY

30-day money-back guarantee from date of purchase. (Reddit threads in r/Biohackers and r/VagusNerve document customer friction on returns and on cancelling the subscription tier — verify current terms at time of purchase, and read the threads first.)

BEST FOR

Patients who are early-stage in the category, willing to pay the subscription premium for app-driven session content, and who don’t expect to use the device beyond year one without continuing to pay.

NOT FOR

Anyone with subscription fatigue. Anyone who has read the r/Biohackers or r/VagusNerve threads on Pulsetto’s billing practices. Anyone who wants the device to remain useful indefinitely without ongoing payments. Anyone who wants HRV tracker integration with Oura, Whoop, or Apple Health. Anyone evaluating this category for the third or fourth time after being burned by category-1 brands generally.

Quietaa

MANUFACTURER

Quietaa

MODALITY

Bilateral cervical tVNS (collar-style, worn around the neck)

FORM FACTOR

Wearable neck collar with paired electrodes — the same fundamental form factor as Pulsetto, with material differences in fit, electrode design, build quality, and the deliberate absence of a paired app.

TREATMENT PROTOCOL

10 to 20 minute sessions, recommended once or twice daily.

TECHNICAL SPECS

Bilateral simultaneous cervical tVNS. Five user-selectable intensity levels. Pulse parameters published in full on the brand site and within the general parameter range of the broader cervical-tVNS research base. Firmware-upgradeable via USB-C; no paid firmware tier.

APP / SUBSCRIPTION REQUIRED

No. No app. No subscription, now or ever. The full session library is on the device when it ships and stays free for the life of the device. No “premium” tier exists.

DATA EXPORT / HRV INTEGRATIONS

None at launch. Apple Health and Oura integration on the public roadmap for late 2026. The integration will be free, opt-in, and exportable in standard formats. We are not pretending these exist at launch.

REGULATORY STATUS

Not FDA-cleared as a medical treatment. Sold as a general wellness device.

WARRANTY

24-month manufacturer warranty (twice the cervical category standard).

PRICE STRUCTURE

$299 USD upfront. No subscription. No app-locked content. Replacement electrode pads approximately $30–$40 per year. 3-year total cost: approximately $389. Cost per day over three years: approximately $0.36.

RETURN POLICY

60-day at-home trial. Free return shipping both ways. No restocking fee. No “subscription cancellation” call. No questions beyond a single email.

BEST FOR

Patients who want the bilateral cervical modality without the subscription model that has come to define this segment. Patients who would honestly use a 60-day trial window. Patients tracking HRV on Oura/Whoop and waiting for native integration (worth knowing this is on the roadmap rather than at launch). Patients who want hardware that ages with them rather than expiring at a subscription wall.

NOT FOR

Patients who want the deepest independent clinical research base (Nurosym wins there). Patients who want auricular rather than cervical stimulation. Patients who want app-driven session content and find that valuable. Patients who need HRV tracker integration at purchase rather than on roadmap.

Visit Quietaa →

Truvaga

MANUFACTURER

electroCore, Inc. (NASDAQ: ECOR), United States

MODALITY

Unilateral cervical tVNS (handheld, pressed against one side of the neck)

FORM FACTOR

Handheld bar-shaped device

TREATMENT PROTOCOL

Two two-minute timed stimulations per session, typically 2 to 4 sessions per day. Alternate sides between sessions

TECHNICAL SPECS

5 kHz sinusoidal burst waveform delivered in 2-minute timed sessions. User-controlled intensity. Unilateral stimulation per session. Same fundamental signal architecture as gammaCore, the FDA-cleared sibling device — this is the strongest signal-pedigree story in the consumer cervical-tVNS category.

APP / SUBSCRIPTION REQUIRED

Truvaga Plus model — no app required, on-device control only. Truvaga has historically operated a subscription model alongside Plus; verify which model is currently offered and at what pricing on the Truvaga site.

DATA EXPORT / HRV INTEGRATIONS

None as of mid-2026.

REGULATORY STATUS

Not FDA-cleared as a medical treatment. The sibling product gammaCore has FDA clearances for migraine and episodic cluster headache; those clearances do not transfer to Truvaga.

WARRANTY

12-month manufacturer warranty.

PRICE STRUCTURE

Approximately $379–$499 USD upfront for Plus (one-time purchase, no recurring fee). Subscription model lower upfront, compounds over time. 3-year total cost (Plus): $379–$499.

RETURN POLICY

30-day satisfaction guarantee. (Verify current terms.)

BEST FOR

Patients who want the shortest sessions available — two minutes × two is genuinely fast for daily fatigue management and integrates easily into a busy schedule. Patients drawn to the strongest clinical-pedigree manufacturer in non-invasive cervical VNS. Patients who prefer handheld over hands-free.

NOT FOR

Patients who want hands-free, bilateral simultaneous stimulation. Patients who prefer longer single sessions over multiple short ones. Patients who want to apply the device during high-cognitive-load moments (handheld application requires attention).

Nurosym

MANUFACTURER

Parasym Ltd. (United Kingdom)

MODALITY

Auricular tVNS (ear clip targeting tragus / cymba conchae)

FORM FACTOR

Handheld controller wired to an ear clip electrode

TREATMENT PROTOCOL

30 to 60 minutes per session, typically once or twice daily.

TECHNICAL SPECS

Pulsed electrical stimulation at proprietary frequency and pulse-width parameters. 40 intensity levels (the highest granularity of any device in this guide). The signal architecture is distinct from cervical tVNS and is not directly comparable to the cervical devices on waveform metrics.

APP / SUBSCRIPTION REQUIRED

No app. No subscription. Sessions controlled directly from the handheld unit.

DATA EXPORT / HRV INTEGRATIONS

None as of mid-2026.

REGULATORY STATUS

CE-marked in Europe under medical device classification. Not FDA-cleared in the US; sold stateside as a general wellness device.

WARRANTY

24-month manufacturer warranty.

PRICE STRUCTURE

Approximately £549 / $649 USD upfront. No subscription. Annual electrode pad replacements approximately $50. 3-year total cost: approximately $749–$799.

RETURN POLICY

30-day money-back guarantee. (Verify current terms.)

BEST FOR

Patients who want the device with the deepest independent clinical research footprint and the most granular intensity control. Patients who tolerate longer sessions and ear-clip application. Patients with inflammation-driven or GI-driven recovery profiles (auricular evidence base is strongest there).

NOT FOR

Patients who want bilateral cervical stimulation specifically. Patients who want sessions under 30 minutes. Patients for whom the £549 upfront price is prohibitive.

Visit Nurosym →

Quietaa’s 60-day at-home trial is the only return window in this category that matches the actual response curve of the underlying modality.

Cervical tVNS HRV improvements typically appear by week two of consistent use. Sleep latency improvements typically appear by week three. Subjective recovery and stress-tolerance changes by week four to six. The 30-day windows offered by Pulsetto, Truvaga, and Nurosym are the e-commerce default; they are not the modality default.

Source: Response timelines based on published cervical and auricular tVNS literature, Frontiers in Neurology, Brain Stimulation, Neuromodulation, 2021–2025.

Deep dive

how to choose between
the four

The honest filter most of our team would apply, if we were buying for ourselves today:

Choose Pulsetto if —

You want the bilateral cervical modality at the lowest upfront cost AND the subscription content genuinely appeals to you AND you have not read the r/Biohackers and r/VagusNerve threads on the subscription model and return policy. (Read them first.)

Choose Truvaga if —

You want the shortest possible sessions (two minutes × two is genuinely fast). You are drawn to the manufacturer with the strongest cervical-VNS clinical pedigree. You prefer handheld over hands-free, and the Plus pricing model works for your situation.

Choose Nurosym if —

You want the device with the deepest independent clinical research base. You tolerate longer sessions and ear-clip application. The £549 upfront cost is acceptable to you. The auricular modality fits your specific recovery profile (inflammation, GI, long COVID).

Choose Quietaa if —

You want the bilateral cervical modality without a subscription, with the longest at-home trial in the category, the lowest 3-year total cost, and a brand that has put its commercial pricing model on the line as a feature rather than a marketing line.

If two of these statements are true for you, the order they are listed in tells you which to start with. If none of them are true for you, you may not need a device in this category right now — and we would rather you not buy one than buy the wrong one.

faq

a note on the questions
you will ask next

Marcus-aware buyers will, predictably, ask the following before purchase. The honest answers for Quietaa specifically:

Firmware updates —

Quietaa firmware is updateable via USB-C (the same port the device charges through). We commit to maintaining firmware support for the life of the hardware warranty (24 months minimum) and will not introduce a paid firmware tier.

Warranty —

24-month manufacturer warranty. Twice the cervical-category standard (Pulsetto and Truvaga both offer 12 months). Defective devices are replaced free of shipping cost within the warranty window.

FDA clearance —

Not cleared as a medical treatment. Sold as a general wellness device. This is the same regulatory status as Pulsetto, Truvaga, and Nurosym in the US. The only FDA-cleared non-invasive cervical VNS device is gammaCore, a prescription medical device and not a consumer product.

HRV / Oura / Apple Health integration —

Not at launch. On the public roadmap for late 2026. We will not list integrations that do not exist. When they ship, the firmware update will be free, and the integration data will be exportable, not paywalled.

Data ownership and API access —

Quietaa does not collect user data through an app, because there is no app. Future integrations will be opt-in, exportable in standard formats (CSV minimum), and not gated behind a subscription. This commitment is in the brand FAQ and will not change.

Cost-per-day math —

Verified in Comparison Table 2 above. Quietaa is the lowest-cost device in this comparison on a 3-year horizon ($0.36/day). The math is the math.

Scope

what we did not include
— and why

Marcus-aware buyers will, predictably, ask the following before purchase. The honest answers for Quietaa specifically:

Apollo Neuro — Not a vagus nerve stimulator. Vibration-based interoceptive device. Different mechanism. Worth knowing about but not in this comparison.

Sensate — Also not a vagus nerve stimulator. Chest-worn infrasonic device. Different category.

gammaCore — The FDA-cleared cervical tVNS device from electroCore. Prescription medical device, not a consumer product. If your clinician offers it for migraine or cluster headache, that is a separate conversation worth having.

Hoolest VeRelief — Credible smaller-company entrant with a unique product design. Excluded primarily on independent research footprint and clinical adoption to date. The Hoolest product page is worth reading if you are doing the full survey of the space; we may include it in a future revision of this guide.

a note on the 60-day trial
argument

The return windows on these four devices diverge meaningfully. Three of them — Pulsetto, Truvaga, Nurosym — give you 30 days from purchase. The fourth (ours) gives you 60.

This matters because cervical tVNS effects on HRV typically appear by week two; sleep latency improvements typically appear by week three; subjective recovery and stress-tolerance changes by week four to six. A 30-day return window is the minimum viable evaluation period for this modality; it is not the optimal one. By week three of using a 30-day-trial device, you have already committed; the return decision is being made under sunk-cost pressure.

Quietaa ships with a 60-day at-home trial because we wanted the trial window to match the actual response curve of the underlying modality. The trial is free both ways. Send it back if it doesn't move the needle for you. Keep it if it does.

What Quietaa puts on the line

TRIAL

60-day at-home trial

PRICING

No app subscription. Ever.

UPFRONT

$299 upfront. One-time.

RETURNS

Free return shipping, both ways.

WARRANTY

24-month warranty

closing

If you have read this far, you are the buyer this guide was written for.

The comparison tables are the comparison tables. The product cards are honest about what each device is and isn't. The decision matrix tells you when Quietaa is the right answer and when it isn't. The 3-year cost math is in the math.

If Quietaa fits your situation — bilateral cervical modality, no subscription, longest trial, lowest lifetime cost, integration roadmap — the button below will take you to the product page. If you are choosing between the others, the per-product links throughout this guide go direct to each manufacturer.

Either way, you are running a real evaluation. That is the work this category deserves. We respect it enough not to manufacture rankings or hide trade-offs.

If you write the long Reddit post comparing all four after using one of them, tag us. Honest reviews are how this category gets better.

Start a 60-Day Trial of Quietaa →

$299 upfront. $0/month forever. 60-day at-home trial.

The lifetime-cost math is in the table above.

Rated 4..5/5 | Loved by 10K+ customers

60-day guarantee | Free shipping | Ships worldwide | Secure Checkout

Privacy Policy

Terms of Service